Total assets grew 188% to $99.8 million; DaaS segment delivered over $10 million in first full year of operations
Miami, FL--(Emerging Growth Newswire – April 29, 2026) – EmergingGrowth.com, a leading independent small cap media portal with an extensive history...
Total assets grew 188% to $99.8 million; DaaS segment delivered over $10 million in first full year of operations
Miami, FL--(Emerging Growth Newswire – April...
Total assets grew 188% to $99.8 million; DaaS segment delivered over $10 million in first full year of operations
Miami, FL--(Emerging Growth Newswire – April...
The first step in creating a new altcoin is to develop a blockchain. One of the simplest ways to start is with one of the many available tutorials online. For example, Smashing Magazine hosts one that walks potential crypto developers through the process of building a blockchain in Node.js.
Due to the increasing attention, cryptocurrencies are flourishing. Coinbase's move to establish instant withdrawal is a step in the right direction for crypto investors. On a short-term level, those who use cryptocurrencies or Coinbase will benefit from immediate transfer funds.
Among small-capitalization companies in the Covid-19 race, Tonix Pharmaceuticals (NASDAQ:TNXP) may be worth consideration with what I would term “dumb money.” Currently, TNXP stock is trading hands for less than a buck, which immediately tells you something about this opportunity’s risk profile.
The recent pandemic brought with it both a collapse in energy prices and stock markets, followed by a massive run-up in stocks to which big oil majors like Lukoil (OTCMKTS: LUKOY), Gazprom (OTCMKTS: OGZPY), Total S.A. (NYSE: TOT), Exxon (NYSE: XOM), BP plc (NYSE: BP), Chevron (NYSE: CVX), and Phillips 66 (NYSE: PSX) have only marginally benefited from. With the energy shakeout continuing, unexpected new winners have emerged servicing regional niche markets who are poised to make serious cash flow.
Galectin Therapeutics Inc. (NASDAQ: GALT) shot up close to 32.4% on Monday on record breaking volume of 4.9 million shares in anticipation of a long awaited investor conference call at 4PM ET on September 29th. In after hours trading the stock continues to climb to $4.20. GALT has one of the worst track records when it comes to shareholder communications with only 9 press releases this year, so it's easy to see why shareholders might be excited and speculating on news during the conference. GALT’s long term holders have pointed to outgoing CEO Harold Shlevin for the lack of communication while he focused on finishing the NASH phase 3 clinical trial design which took close to 2 years to complete.